The management of lung adenocarcinoma with brain metastases (BMs) is particularly challenging when BRAF-V600E mutations emerge as a resistance mechanism to EGFR tyrosine kinase inhibitors. This evidence concerns the gene EGFR and lung adenocarcinoma.